Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (4214)	4/4/2006 12:24:50 AM
From: DewDiligence_on_SI	Respond to of 12215

[NVS] licenses IDIX's NM283..wonder how WS will like this given the recent disclosure of GI effects WS wasn’t too impressed, evidently, but I was and picked up some IDIX after the NVS opt-in. Where else is there an opportunity to buy shares of a drug-discovery company with one drug pending approval for a large indication, another drug to enter phase-3 this year for a large indication, a blue-chip partner (Novartis), well-respected management, and a solid balance sheet… for less than the IPO price in 2004?